KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Intangibles (2016 - 2023)

Historic Intangibles for Inovio Pharmaceuticals (INO) over the last 15 years, with Q1 2023 value amounting to $2.0 million.

  • Inovio Pharmaceuticals' Intangibles fell 1807.53% to $2.0 million in Q1 2023 from the same period last year, while for Mar 2023 it was $2.0 million, marking a year-over-year decrease of 1807.53%. This contributed to the annual value of $2.1 million for FY2022, which is 1890.43% down from last year.
  • Latest data reveals that Inovio Pharmaceuticals reported Intangibles of $2.0 million as of Q1 2023, which was down 1807.53% from $2.1 million recorded in Q4 2022.
  • Over the past 5 years, Inovio Pharmaceuticals' Intangibles peaked at $4.5 million during Q1 2019, and registered a low of $2.0 million during Q1 2023.
  • Over the past 5 years, Inovio Pharmaceuticals' median Intangibles value was $3.0 million (recorded in 2021), while the average stood at $3.1 million.
  • Its Intangibles has fluctuated over the past 5 years, first plummeted by 2240.05% in 2019, then crashed by 1481.06% in 2020.
  • Quarter analysis of 5 years shows Inovio Pharmaceuticals' Intangibles stood at $3.7 million in 2019, then fell by 14.81% to $3.1 million in 2020, then dropped by 16.54% to $2.6 million in 2021, then decreased by 18.9% to $2.1 million in 2022, then decreased by 3.85% to $2.0 million in 2023.
  • Its Intangibles was $2.0 million in Q1 2023, compared to $2.1 million in Q4 2022 and $2.2 million in Q3 2022.